​

Amylyx Pharmaceuticals (AMLX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AMLX Stock Forecast

Amylyx Pharmaceuticals (AMLX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $8.25, with a high of $11.00 and a low of $4.00. This represents a 138.44% increase from the last price of $3.46.

- $4 $8 $12 $16 $20 High: $11 Avg: $8.25 Low: $4 Last Closed Price: $3.46

AMLX Stock Rating

Amylyx Pharmaceuticals stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

AMLX Forecast vs Benchmarks

TypeNameUpside
StockAmylyx Pharmaceuticals138.44%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-18
Avg Price Target-$11.00$5.88
Last Closing Price$3.46$3.46$3.46
Upside/Downside-217.92%69.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25123--6
Dec, 24124--7
Nov, 24126--9
Oct, 24116--8
Sep, 24116--8
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 18, 2024Joel BeattyRobert W. Baird$11.00$4.76131.09%217.92%
Oct 23, 2024Geoff MeachamBank of America Securities$10.00$4.53120.75%189.02%
Oct 18, 2024Andrew FeinH.C. Wainwright$8.00$3.92104.08%131.21%
Oct 18, 2024Marc GoodmanLeerink Partners$4.00$3.922.04%15.61%
May 14, 2024Graig SuvannavejhMizuho Securities$3.00$1.8264.84%-13.29%
Apr 11, 2024Joel BeattyRobert W. Baird$3.00$2.4621.95%-13.29%
Apr 04, 2024Neena Bitritto-GargDeutsche Bank$4.00$2.6252.67%15.61%
Mar 17, 2024Graig SuvannavejhMizuho Securities$4.00$3.2423.46%15.61%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024Bank of America SecuritiesBuyupgrade
Oct 18, 2024H.C. WainwrightBuyBuyhold
Oct 18, 2024Leerink PartnersMarket PerformMarket Performhold
Jul 12, 2024Goldman SachsUnderperformUnderperformhold
Jul 11, 2024Goldman SachsNeutralNeutralhold
Jun 24, 2024H.C. WainwrightBuyBuyhold
May 10, 2024H.C. WainwrightBuyBuyhold
Apr 08, 2024H.C. WainwrightBuyBuyhold
Apr 04, 2024Deutsche BankBuyBuyhold
Mar 14, 2023CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.59$-3.39$0.73-----
Avg Forecast$-15.35$-3.49$0.90$-4.29$-1.61$-1.38$-1.20$-1.00
High Forecast$-15.35$-3.49$0.79$-4.39$-1.87$-2.43$-2.54$-1.00
Low Forecast$-15.35$-3.49$0.98$-4.12$-1.08$-0.72$-0.38$-1.00
Surprise %-89.64%-2.87%-18.89%-----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$285.00K$22.23M$380.79M-----
Avg Forecast$528.33K$4.42M$379.74M$87.94M$114.53M$215.00K$6.33M$29.14M
High Forecast$528.30K$4.42M$377.56M$87.92M$114.53M$215.00K$6.33M$29.14M
Low Forecast$528.36K$4.42M$382.02M$87.96M$114.53M$215.00K$6.33M$29.14M
Surprise %-46.06%402.66%0.27%-----

Net Income Forecast

$-2B $-1B $-700M $-300M $100M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-87.88M$-198.38M$49.27M-----
Avg Forecast$-1.07B$-244.32M$61.82M$-297.81M$-103.83M$-83.57M$-70.33M$-70.17M
High Forecast$-1.07B$-244.33M$54.95M$-307.26M$-131.14M$-170.08M$-177.78M$-70.17M
Low Forecast$-1.07B$-244.29M$68.69M$-288.36M$-75.69M$-50.39M$-26.60M$-70.17M
Surprise %-91.82%-18.80%-20.30%-----

AMLX Forecast FAQ

Is Amylyx Pharmaceuticals stock a buy?

Amylyx Pharmaceuticals stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Amylyx Pharmaceuticals is a favorable investment for most analysts.

What is Amylyx Pharmaceuticals's price target?

Amylyx Pharmaceuticals's price target, set by 5 Wall Street analysts, averages $8.25 over the next 12 months. The price target range spans from $4 at the low end to $11 at the high end, suggesting a potential 138.44% change from the previous close price of $3.46.

How does Amylyx Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Amylyx Pharmaceuticals stock forecast shows a 138.44% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Amylyx Pharmaceuticals over the past three months?

  • January 2025: 16.67% Strong Buy, 33.33% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 14.29% Strong Buy, 28.57% Buy, 57.14% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.

What is Amylyx Pharmaceuticals’s EPS forecast?

Amylyx Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is -4.29 for 2024, a -687.67% decrease from the reported $0.73 in 2023. The prediction for 2025 is $-1.61, $-1.38 for 2026, $-1.2 for 2027, and $-1 for 2028.

What is Amylyx Pharmaceuticals’s revenue forecast?

Amylyx Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $87.94M for 2024, a -76.91% decrease from the reported $380.79M in 2023. The forecast for 2025 is $114.53M, $215K for 2026, $6.33M for 2027, and $29.14M for 2028.

What is Amylyx Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Amylyx Pharmaceuticals's average annual net income forecast is $-298M for 2024, reflecting a -704.44% decrease from the reported $49.27M in 2023. The projection for 2025 is $-104M, $-83.569M for 2026, $-70.333M for 2027, and $-70.166M for 2028.